MX2009011573A - Metodos de reduccion de nefrotoxicidad en sujetos administrados con nucleosido. - Google Patents
Metodos de reduccion de nefrotoxicidad en sujetos administrados con nucleosido.Info
- Publication number
- MX2009011573A MX2009011573A MX2009011573A MX2009011573A MX2009011573A MX 2009011573 A MX2009011573 A MX 2009011573A MX 2009011573 A MX2009011573 A MX 2009011573A MX 2009011573 A MX2009011573 A MX 2009011573A MX 2009011573 A MX2009011573 A MX 2009011573A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- nucleoside
- subjects administered
- reducing nephrotoxicity
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 206010029155 Nephropathy toxic Diseases 0.000 title 1
- 230000007694 nephrotoxicity Effects 0.000 title 1
- 231100000417 nephrotoxicity Toxicity 0.000 title 1
- 239000002777 nucleoside Substances 0.000 title 1
- 150000003833 nucleoside derivatives Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- WXJFKKQWPMNTIM-VWLOTQADSA-N [(2s)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid Chemical compound CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@H](CO)CN1C=CC(N)=NC1=O WXJFKKQWPMNTIM-VWLOTQADSA-N 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91453207P | 2007-04-27 | 2007-04-27 | |
| PCT/US2008/005322 WO2008133966A1 (en) | 2007-04-27 | 2008-04-25 | Methods of reducing nephrotoxicity in subjects administered with nucleoside |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009011573A true MX2009011573A (es) | 2010-01-20 |
Family
ID=39523817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009011573A MX2009011573A (es) | 2007-04-27 | 2008-04-25 | Metodos de reduccion de nefrotoxicidad en sujetos administrados con nucleosido. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20120010170A1 (https=) |
| EP (1) | EP2155257B1 (https=) |
| JP (2) | JP2010525063A (https=) |
| CN (2) | CN102702260A (https=) |
| AU (1) | AU2008246195B2 (https=) |
| CA (1) | CA2685285A1 (https=) |
| ES (1) | ES2609095T3 (https=) |
| MX (1) | MX2009011573A (https=) |
| WO (1) | WO2008133966A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008535862A (ja) | 2005-04-08 | 2008-09-04 | キメリクス，インコーポレイテッド | ポックスウイルス感染の治療のための化合物、組成物および方法 |
| EP2254582B1 (en) | 2008-01-25 | 2016-01-20 | Chimerix, Inc. | Methods of treating viral infections |
| US8614200B2 (en) | 2009-07-21 | 2013-12-24 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
| WO2011017253A1 (en) * | 2009-08-03 | 2011-02-10 | Chimerix, Inc. | Composition and methods of treating viral infections and viral induced tumors |
| CN102665729A (zh) * | 2009-10-30 | 2012-09-12 | 奇默里克斯公司 | 用于治疗病毒相关性疾病的方法 |
| WO2011053812A1 (en) * | 2009-10-30 | 2011-05-05 | Chimerix, Inc. | Methods of treating viral associated diseases |
| US9006218B2 (en) | 2010-02-12 | 2015-04-14 | Chimerix Inc. | Nucleoside phosphonate salts |
| US9278135B2 (en) | 2010-04-26 | 2016-03-08 | Chimerix Inc. | Methods of treating retroviral infections and related dosage regimes |
| AU2015201895B2 (en) * | 2010-08-31 | 2016-11-17 | Emergent Biodefence Operations Lansing Llc | Phosphonate ester derivatives and methods of synthesis thereof |
| ES2604137T3 (es) * | 2010-08-31 | 2017-03-03 | Chimerix, Inc. | Derivados de éster de fosfonato y métodos de síntesis de los mismos |
| SE1450131A1 (sv) | 2011-10-21 | 2014-05-07 | Abbvie Inc | DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| DE112012002748T5 (de) | 2011-10-21 | 2014-07-31 | Abbvie Inc. | Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon |
| ES2874774T3 (es) | 2011-12-22 | 2021-11-05 | Geron Corp | Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros |
| EP2869823A4 (en) * | 2012-07-03 | 2016-03-16 | Chimerix Inc | METHOD FOR THE TREATMENT OF RETROVIRUS INFECTIONS AND RELATED DOSING PLANS |
| EA201892769A3 (ru) | 2013-03-15 | 2019-08-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Сложные диэфиры ациклических нуклеозидфосфонатов |
| DK2999476T3 (en) | 2013-11-15 | 2018-09-03 | Chimerix Inc | MORPHIC FORMS OF HEXADECYLOXYPROPYL PHOSPHONATE TESTERS |
| BR112017005111B1 (pt) | 2014-09-15 | 2023-02-14 | The Regents Of The University Of California | Compostos análogos de nucleotídeo acíclico, composição farmacêutica contendo tais compostos, e usos da composição no tratamento de uma infecção por papilomavírus |
| WO2017048956A1 (en) | 2015-09-15 | 2017-03-23 | The Regents Of The University Of California | Nucleotide analogs |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| EP4295853A3 (en) * | 2016-06-28 | 2024-03-06 | Emergent BioDefense Operations Lansing LLC | Formulations of brincidofovir |
| WO2018156879A1 (en) * | 2017-02-23 | 2018-08-30 | Chimerix, Inc. | Treatment of adenovirus with brincidofovir |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| AU2021224588B2 (en) | 2020-02-18 | 2024-07-18 | Gilead Sciences, Inc. | Antiviral compounds |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| EP4323362B1 (en) | 2021-04-16 | 2025-05-07 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| AU2022328698B2 (en) | 2021-08-18 | 2025-02-20 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| IL318465A (en) | 2022-07-21 | 2025-03-01 | Antiva Biosciences Inc | Compositions and dosage forms for the treatment of HPV infection and HPV-induced neoplasia |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60038038T2 (de) * | 1999-12-03 | 2009-02-12 | The Regents of The University of California at San Diego, La Jolla | Phosphonatverbindungen |
| JP2005508945A (ja) * | 2001-10-06 | 2005-04-07 | メリアル リミテッド | Ｃｐｇ配合物及び関連方法 |
| JP2008535862A (ja) * | 2005-04-08 | 2008-09-04 | キメリクス，インコーポレイテッド | ポックスウイルス感染の治療のための化合物、組成物および方法 |
| CN100396689C (zh) * | 2006-03-07 | 2008-06-25 | 中国医学科学院医药生物技术研究所 | 一组具有抑制hiv-1/hbv病毒复制活性的替诺福韦单酯化合物 |
-
2008
- 2008-04-25 WO PCT/US2008/005322 patent/WO2008133966A1/en not_active Ceased
- 2008-04-25 CA CA002685285A patent/CA2685285A1/en active Pending
- 2008-04-25 US US12/597,046 patent/US20120010170A1/en not_active Abandoned
- 2008-04-25 JP JP2010506270A patent/JP2010525063A/ja not_active Withdrawn
- 2008-04-25 CN CN2012101543928A patent/CN102702260A/zh active Pending
- 2008-04-25 AU AU2008246195A patent/AU2008246195B2/en active Active
- 2008-04-25 EP EP08743275.3A patent/EP2155257B1/en active Active
- 2008-04-25 ES ES08743275.3T patent/ES2609095T3/es active Active
- 2008-04-25 MX MX2009011573A patent/MX2009011573A/es active IP Right Grant
- 2008-04-25 CN CN200880013876A patent/CN101678122A/zh active Pending
-
2014
- 2014-11-18 JP JP2014233457A patent/JP2015063538A/ja active Pending
-
2016
- 2016-04-13 US US15/098,011 patent/US20160303147A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015063538A (ja) | 2015-04-09 |
| EP2155257A1 (en) | 2010-02-24 |
| CN101678122A (zh) | 2010-03-24 |
| EP2155257B1 (en) | 2016-10-05 |
| CN102702260A (zh) | 2012-10-03 |
| US20160303147A1 (en) | 2016-10-20 |
| US20120010170A1 (en) | 2012-01-12 |
| AU2008246195A1 (en) | 2008-11-06 |
| AU2008246195B2 (en) | 2014-06-05 |
| CA2685285A1 (en) | 2008-11-06 |
| ES2609095T3 (es) | 2017-04-18 |
| WO2008133966A1 (en) | 2008-11-06 |
| JP2010525063A (ja) | 2010-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009011573A (es) | Metodos de reduccion de nefrotoxicidad en sujetos administrados con nucleosido. | |
| TN2013000421A1 (en) | 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | |
| WO2012142093A3 (en) | 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | |
| MA32633B1 (fr) | Formes cristallines d'un derive 2-thiazolyl-4-quinolinyl-oxy, un inhibiteur puissant du vhc | |
| NZ627824A (en) | Antiviral combinations involving (4r,12as)-n-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2hpyrido[1’,2’:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide | |
| CY1117576T1 (el) | Δινουκλεοτιδικα προφαρμακα | |
| MX2009006764A (es) | Pirimidinonas biciclicas y usos de la misma. | |
| EP4378482A3 (en) | Dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates | |
| EA201170527A1 (ru) | Фармацевтические композиции, включающие соединения бороновой кислоты | |
| TW200630344A (en) | Tetracyclic indole derivatives as antiviral agents | |
| WO2008030617A3 (en) | Cancer therapy with cantharidin and cantharidin analogs | |
| MX372534B (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
| MX2010007374A (es) | Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos. | |
| EA201591390A1 (ru) | Пиразол[1,5-a]пиримидины для противовирусного лечения | |
| MY145856A (en) | Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis c virus | |
| WO2007029029A3 (en) | Tetracyclic indole derivatives as antiviral agents | |
| GB0413087D0 (en) | Therapeutic compounds | |
| EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
| WO2006029081A3 (en) | Nucleoside-lipid conjugates, their method of preparation and uses thereof | |
| CY1116664T1 (el) | Χρηση ενος ινδαζολο-μεθοξυ-αλκανοϊκου οξεος για την παρασκευη μιας φαρμακευτικης συνθεσης | |
| ECSP099506A (es) | Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos | |
| WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
| WO2010054068A3 (en) | Cyclic adenosine monophosphates for reducing the formation of adhesions | |
| MA31630B1 (fr) | Dérivés de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides et de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazépine-7-carboxamides, leur préparation et leur application en thérapeutique | |
| IL191928A0 (en) | Triazoloanilinopyrimidine derivatives for use as antiviral agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |